National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 32619 [E9-16100]
Download as PDF
Federal Register / Vol. 74, No. 129 / Wednesday, July 8, 2009 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Pain, Morphine and
the Developing Brain: School Age Outcomes.
Date: July 31, 2009.
Time: 12 p.m. to 4 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852, (Telephone Conference Call).
Contact Person: Peter Zelazowski, PhD,
Scientific Review Officer, Division of
Scientific Review, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6100 Executive
Boulevard, Rm. 5B01, Bethesda, MD 20892–
7510, 301–435–6902,
peter.zelazowski@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: June 30, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–16109 Filed 7–7–09; 8:45 am]
BILLING CODE 4140–01–P
mstockstill on DSKH9S0YB1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
amended (5 U.S.C. App.) notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.
App., as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for type 1
diabetes. The outcome of the evaluation
will be a decision whether NIDDK
should support the request and make
available contract resources for
development of the potential
therapeutic to improve the treatment or
prevent the development of type 1
diabetes and its complications. The
research proposals and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the proposed research
projects, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Type 1 Diabetes—
Rapid Access to Intervention Development
Special Emphasis Panel; National Institute of
Diabetes and Digestive and Kidney Diseases.
Date: July 22, 2009.
Time: 11 a.m.–1 p.m.
Agenda: To evaluate requests for
preclinical development resources for
potential new therapeutics for type 1 diabetes
and its complications.
Place: 6707 Democracy Boulevard,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Dr. Myrlene Staten, Senior
Advisor, Diabetes, Translation Research,
Division of Diabetes, Endocrinology and
Metabolic Diseases, NIDDK, NIH, 6707
Democracy Boulevard, Bethesda, MD 20892–
5460, 301–402–7886.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 98.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: July 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–16100 Filed 7–7–09; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Nov<24>2008
17:23 Jul 07, 2009
Jkt 217001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Research
Resources; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Research Resources Special Emphasis Panel;
ARRA Research Networking.
Date: August 20, 2009.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Guo Zhang, PhD, Scientific
Review Officer, National Center for Research
Resources, or National Institutes of Health,
6701 Democracy Blvd., 1 Democracy Plaza,
Room 1064, Msc 4874, Bethesda, MD 20892–
4874, 301–435–0812, zhanggu@mail.nih.gov.
Name of Committee: National Center for
Research Resources Special Emphasis Panel;
ARRA Resource Discovery.
Date: August 21, 2009.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Guo Zhang, PhD, Scientific
Review Officer, National Center for Research
Resources, or National Institutes of Health,
6701 Democracy Blvd., 1 Democracy Plaza,
Room 1064, Msc 4874, Bethesda, MD 20892–
4874, 301–435–0812, zhanggu@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research; 93.371, Biomedical
Technology; 93.389, Research Infrastructure,
93.306, 93.333; 93.702, ARRA Related
Construction Award, National Institutes of
Health, HHS)
Dated: July 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–16095 Filed 7–7–09; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
32619
E:\FR\FM\08JYN1.SGM
08JYN1
Agencies
[Federal Register Volume 74, Number 129 (Wednesday, July 8, 2009)]
[Notices]
[Page 32619]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-16100]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.) notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C. App., as amended. The purpose of this meeting is to evaluate
requests for preclinical development resources for potential new
therapeutics for type 1 diabetes. The outcome of the evaluation will be
a decision whether NIDDK should support the request and make available
contract resources for development of the potential therapeutic to
improve the treatment or prevent the development of type 1 diabetes and
its complications. The research proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Type 1 Diabetes--Rapid Access to Intervention
Development Special Emphasis Panel; National Institute of Diabetes
and Digestive and Kidney Diseases.
Date: July 22, 2009.
Time: 11 a.m.-1 p.m.
Agenda: To evaluate requests for preclinical development
resources for potential new therapeutics for type 1 diabetes and its
complications.
Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes,
Translation Research, Division of Diabetes, Endocrinology and
Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda,
MD 20892-5460, 301-402-7886.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: July 1, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-16100 Filed 7-7-09; 8:45 am]
BILLING CODE 4140-01-P